Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?

Key Takeaways Bristol Myers emerges as the stronger near-term pick over Merck.BMY's new drugs, label expansions and $2B cost-savings plan support 2026 margins.MRK faces Gardasil weakness, Keytruda exclusivity loss and a $2.5B generic headwind.Merck & Co. (MRK) and Bristol Myers Squibb (BMY) are major global drugmakers with expansive, diversified portfolios.Merck stands out for its leadership in oncology, complemented by strong positions in infectious diseases and vaccines.Bristol Myers, meanwhile, concentra ...